Home·Indications·Synovial sarcoma

Synovial sarcoma

Solid tumorIndication · Soft Tissue

Synovial Sarcoma is a rare soft-tissue cancer driven by characteristic chromosomal translocations. Molecular confirmation supports diagnosis and treatment planning.

Approvals
2
Therapies
6
Biomarkers
9
Mapped tests
7

Biomarkers used in this indication

Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.

Indication-specific biomarkers

Defined explicitly for Synovial sarcoma in FDA labeling.

BiomarkerBiomarker criteriaTherapies
HLA
  • Eligible alleles: HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles. Exclusion alleles: HLA-A*02:05 and its P-group alleles.
TECELRA
Melanoma-associated antigen 4 (MAGE-A4)
  • MAGE-A4 protein overexpression
TECELRA
Tumor-agnostic biomarkers

Defined at the solid tumor level and applicable to Synovial sarcoma and other solid tumor cancers.

BiomarkerBiomarker criteriaTherapies
deficient mismatch repair (dMMR) proteins
  • MLH1, PMS2, MSH2 and MSH6
JEMPERLIKEYTRUDA
MSI-High
  • Microsatellite instability-High
KEYTRUDAJEMPERLI
NTRK1, NTRK2 and NTRK3
  • fusions
VITRAKVIROZLYTREK
RET
  • fusions
RETEVMO
TMB
  • TMB ≥ 10 mutations per megabase
KEYTRUDA

Therapies with biomarker-defined approvals

Each therapy below has at least one FDA companion diagnostic approval tied to Synovial sarcoma. Select a therapy to view the specific approval and eligible tests.

Therapy
JEMPERLI
dostarlimag-gxly · GSK

deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)

2 approvalsView testing pathway →
Therapy
KEYTRUDA
pembrolizumab · Merck

deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)

3 approvalsView testing pathway →
Therapy
RETEVMO
selpercatinib · Eli Lilly

RET (fusions)

1 approvalView testing pathway →
Therapy
ROZLYTREK
entrectinib · Genentech

NTRK1, NTRK2 and NTRK3 (fusions)

1 approvalView testing pathway →
Therapy
TECELRA
afamitresgene autoleucel · Adaptimmune

HLA (Eligible alleles: HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles. Exclusion alleles: HLA-A*02:05 and its P-group alleles.); Melanoma-associated antigen 4 (MAGE-A4) (MAGE-A4 protein overexpression)

2 approvalsView testing pathway →
Therapy
VITRAKVI
larotrectinib · Bayer

NTRK1, NTRK2 and NTRK3 (fusions)

1 approvalView testing pathway →
This indication view is scoped to Synovial sarcoma. You can also explore how it appears alongside other cancers in Know Your Companions™ by searching or filtering on the main map.